Value Co-creation by Compulsory Facebook-Community in Corporate Culture: A Case Study Malaysian Logistic Company

The main purpose of this study was to investigate the value co-creation process using Facebook as compulsory by a company. A new value co-creation model was developed showing how Facebook could be successfully executed as a platform for the value co-creation process with the aim of providing the best possible service to the recipients. This research employed an explanatory case study due to its uniqueness, especially for sufficient and in-depth comprehension of the phenomenon. PKT Logistics Group Sdn Bhd (PKT) was chosen for this study due to its exceptional characteristic of declaring itself as ‘Facebook compulsory’ company in business after Facebook. Data were obtained from interviews, direct observations, and a questionnaire survey of the company’s top management, selected employees, and customers.The proposed model has successfully connected the company’s leader, employees, and customers with each other for attaining the ‘Ba’ in new knowledge creation spirally using Facebook as an effective platform. This has resulted in the achievement of a service-oriented value co-creation process.This research has contributed to create a new model of the value co-creation process involving all the stakeholders via a ‘Facebook community’, which could be useful for other service providers.This study differentiates itself from the restricted application of Facebook in business by focusing on Facebook as compulsory in a corporate culture. The new value co-creation process model thru a ‘Facebook community’ is original and might be first of this type study

Adverse Events as Potential Predictive Factors of Activity in Patients with Advanced HCC Treated with Atezolizumab Plus Bevacizumab

Background In the context of patients with hepatocellular carcinoma (HCC) treated with systemic therapy, the correlation between the appearance of adverse events (AEs) and reported efficacy outcomes is well-known and widely investigated. From other pathological settings, we are aware of the prognostic and predictive value of the occurrence of immune-related AEs in patients treated with immune-checkpoint inhibitors. Objective This retrospective multicenter real-world study aims to investigate the potential prognostic value of AEs in patients with HCC treated with atezolizumab plus bevacizumab in the first-line setting. Patients and methods The study population consisted of 823 patients from five countries (Italy, Germany, Portugal, Japan, and the Republic of Korea). Results Of the patients, 73.3% presented at least one AE during the study period. The most common AEs were proteinuria (29.6%), arterial hypertension (27.2%), and fatigue (26.0%). In all, 17.3% of the AEs were grade (G) 3. One death due to bleeding was reported. The multivariate analysis confirmed the appearance of decreased appetite G < 2 [versus G >= 2; hazard ratio (HR) 0.60; 95% confidence interval (CI) 0.13-0.90; p < 0.01] and immunotoxicity G < 2 (versus G >= 2; HR: 0.70; 95% CI 0.24-0.99; p = 0.04) as independent prognostic factors for overall survival, and the appearance of decreased appetite G < 2 (versus G >= 2; HR: 0.73; 95% CI 0.43-0.95; p = 0.01), diarrhea (yes versus no; HR: 0.57, 95% CI 0.38-0.85; p = 0.01), fatigue (yes versus no; HR: 0.82, 95% CI 0.65-0.95; p < 0.01), arterial hypertension G < 2 (versus G >= 2; HR: 0.68, 95% CI 0.52-0.87; p < 0.01), and proteinuria (yes versus no; HR: 0.79, 95% CI 0.64-0.98; p = 0.03) as independent prognostic factors for progression-free survival. Conclusions As demonstrated for other therapies, there is also a correlation between the occurrence of AEs and outcomes for patients with HCC for the combination of atezolizumab plus bevacizumab

Sequential therapies after atezolizumab plus bevacizumab or lenvatinib first-line treatments in hepatocellular carcinoma patients

Introduction: The aim of this retrospective proof-of-concept study was to compare different second-line treatments for patients with hepatocellular carcinoma and progressive disease (PD) after first-line lenvatinib or atezolizumab plus bevacizumab.Materials and methods: A total of 1381 patients had PD at first-line therapy. 917 patients received lenvatinib as first-line treatment, and 464 patients atezolizumab plus bevacizumab as first-line.Results: 49.6% of PD patients received a second-line therapy without any statistical difference in overall survival (OS) between lenvatinib (20.6 months) and atezolizumab plus bev-acizumab first-line (15.7 months; p = 0.12; hazard ratio [HR] = 0.80). After lenvatinib first-line, there wasn't any statistical difference between second-line therapy subgroups (p = 0.27; sorafenib HR: 1; immunotherapy HR: 0.69; other therapies HR: 0.85). Patients who under-went trans-arterial chemo-embolization (TACE) had a significative longer OS than patients who received sorafenib (24.7 versus 15.8 months, p < 0.01; HR = 0.64). After atezolizumab plus bevacizumab first-line, there was a statistical difference between second-line therapy subgroups (p < 0.01; sorafenib HR: 1; lenvatinib HR: 0.50; cabozantinib HR: 1.29; other therapies HR: 0.54). Patients who received lenvatinib (17.0 months) and those who under-went TACE (15.9 months) had a significative longer OS than patients treated with sorafenib (14.2 months; respectively, p = 0.01; HR = 0.45, and p < 0.05; HR = 0.46).Conclusion: Approximately half of patients receiving first-line lenvatinib or atezolizumab plus bevacizumab access second-line treatment. Our data suggest that in patients progressed to atezolizumab plus bevacizumab, the systemic therapy able to achieve the longest survival is lenvatinib, while in patients progressed to lenvatinib, the systemic therapy able to achieve the longest survival is immunotherapy

A curriculum of MOS (management of service) course based on knowledge science and information science

Innovations can improve the productivity and quality of services and lead to new services. The importance of education to such services innovation has been a focus of discussion all over the world. The Japan Advanced Institute of Science and Technology (JAIST) has established a new education course for services innovation called MOS (management of service). The curriculum of the MOS course is based on the recognition that services in the 21st century are dependent on knowledge science, information science, business science, and transdisciplinary science and technology. In particular, knowledge science including ethnography and brain science and information science that studies the Internet and data management can enhance service quality. This paper describes the concept of JAIST’s MOS course and outlines its curriculum

Conceptualizing Technical and Vocational Education and Training as a Service Through Service-Dominant Logic

Technical and vocational education and training (TVET) plays a pivotal role in equipping young individuals with technical skills and competencies, enhancing their employability. TVET is distinct for its student-centered and industry-oriented features, often involving enterprises in on-site training. In this study, we conceptualized TVET as a service through the lens of service-dominant (S-D) logic, offering a comprehensive exploration of its attributes and values. Our work rigorously validates the fundamental premises of S-D logic within the context of TVET, making the first systematic examination of TVET from a service science perspective. This innovative conceptualization allows us to view TVET as a dynamic process of value co-creation, with students and enterprises as active co-creators. They collaborate and contribute, fostering profound engagement among TVET practitioners, to mitigate TVET challenges through co-creation